Ebru Engin Delipoyraz

6PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 25, 2026
Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.

|May 04, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

|May 04, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

|Mar 28, 2026
Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz

|Dec 11, 2025
Relationship Between Mast Cell Population of Microenvironment and Prognosis in Colorectal Cancer.

Neşe Yeldir, Ebru Engin Delipoyraz, Aslı Çakır

|Apr 12, 2025
Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience.

Harun Muğlu, Erdem Sünger, Maral Martin Mıldanoğlu

Pageof 1

Frequent Collaborators

5 joint publications

Harun Muğlu

5 joint publications

Erdem Sünger

5 joint publications

Maral Martin Mıldanoğlu

5 joint publications

Mehmet Haluk Yücel